



---

[Action Site](#) [COST Action](#) [LinkedIn](#) [YouTube](#) [X-Twitter](#)

### In this edition ...

- Special Issue Invitation: **Disseminating Research on One Health Drugs**
- March Activities **Snapshot**
- Upcoming Events – **April 2025**
- OneHealthdrugs Ambassadors **Announced!**
- OHD Reporting – **Capturing our 1st and 2nd Year Achievements**
- New Dissemination Grants **Available!** STSM grants **announced**
- Upcoming In-Person Events – **Year 3**
- Strategic Stakeholder Engagement – **Driving Results Exploitation (Year 3)**

---

## Message from the Action Chair

---

March 31<sup>st</sup>, 2025

Dear Members of the **OneHealthDrugs** Action,

As spring brightens our days, so does the incredible momentum of the OneHealthdrugs community! With new activities, ambassador announcements, and exciting meetings ahead, April promises to be as lively as a beehive on caffeine. Thanks for keeping the spirit and science blooming—read on and let the inspiration roll in!

---

by [Maria-Paola Costi](#), Action Chair



Maria Paola Costi, Action Chair

---

## Special Issue Invitation: Disseminating Research on One Health Drugs

Dear Colleagues,

COST Action CA21111 - OneHealthDrugs is pleased to announce the upcoming Special Issue (SI) titled "One Health Drugs against Vector-Borne Parasitic Diseases – A Sustainable Chemical/Biological Approach," to be published in the open-access journal Molecules (MDPI).

This Special Issue aims to provide an excellent platform for COST Action members to showcase their latest research on drug development targeting vector-borne parasitic diseases (VBPDs), addressing sustainability, degradability, ecotoxicology, and eco-friendly methodologies. A detailed outline of the Special Issue's aims and scope will be developed collaboratively by the Editorial Team.

We are currently inviting members of the COST Action community to join our Editorial Team as guest editors. We seek to build a diverse group comprising experienced researchers from various relevant fields within our action, as well as motivated early-career researchers.

If you:

Are interested in gaining editorial experience (from initial manuscript submission through peer review to final acceptance),

- Hold a doctoral degree,
- Are an advanced postdoctoral researcher, early-career independent researcher (within 10 years post-PhD), or an experienced independent researcher,
- Wish to actively contribute to the dissemination success of our COST Action,
- 

Please express your interest by contacting Thomas J. Schmidt ([thomschm@uni-muenster.de](mailto:thomschm@uni-muenster.de)), Editor-in-Chief of Molecules, who is coordinating this Special Issue.

We look forward to your valuable contributions.

---

## March Activities Snapshot

In March, our COST Action successfully held two key activities (Detailed outcomes will soon be available on the provided web pages):

Workshop: **Green and Bioinformatic Approaches Including Biodegradability Prediction in Antiparasitic Drug Discovery** ([link](#))

5th OHD Training School: **In Silico Prediction Methods for Ecotoxicity and Bioaccumulation** ([link](#)).

---

## Upcoming Events – April 2025

Mark your calendars for these exciting April events! Check the [OHD website](#) for details:

- **WG2 Organisational Meeting** – 4 April (15:00–16:00 CET, Online)
- **WG5 + HG1 Organisational Meeting** – 10 April (16:00–17:00 CET, Online)
- **Workshop:** Principles of Veterinary Drug Development for PVBD, including Regulatory Aspects, under OneHealth Framework [WG6] – 11 April (14:00–15:00 CET, Online)
- **HG4 Meeting** – Expected on 14 April (Online, time TBA)
- **WG1 Organisational Meeting** – 16 April (15:00–16:00 CET, Online)

# OneHealthdrugs Ambassadors Announced!

---

We are excited to introduce our newly selected **Ambassadors** for the **OneHealthdrugs Academy**:

- Prof. Michael Bertram
- Prof. Farah Faudyn
- Dr. Elisa Uliassi
- Dr. Clara Lima
- Dr. Daniele Aiello

Our ambassadors will actively promote awareness of our core principles:

- optimising drug discovery against vector-borne diseases (VBDs),
- improving therapeutic outcomes for both humans and animals,
- and emphasising sustainability and environmental protection.

More details available [here](#).

---

## OHD Reporting – Capturing our 1st and 2nd Year Achievements

We thank all members to review the extensive work conducted during the first two years of our COST Action. Detailed reports on completed activities, scientific publications, collaborations, patents, projects, and additional outcomes are accessible via our dedicated reporting spreadsheet.

The Chair encourages continued participation from everyone—please regularly update your contributions directly into the [common OHD reporting](#).

[tool](#). Your efforts are crucial for demonstrating the collective impact of our Action and planning future directions.

---

## New Dissemination Grants Available!

Starting this year, we have additional dissemination grants to support our members:

**YRI Conference Grant:** Supports Young Researchers and Innovators (YRIs) presenting their own work (poster or oral) at prestigious external conferences not organised or co-organised by our COST Action.

**ITC Conference Grant:** Funds oral presentations by Action participants affiliated with institutions from Inclusiveness Target Countries (ITC) or Near Neighbour Countries at high-level external conferences.

**Dissemination Conference Grant:** Covers oral presentations highlighting our Action's collective achievements at high-level conferences organised by external entities.

---

## Short Term Scientific Mission (STSM)

***6 STSM applications were submitted and approved.***

The STSM application is closing by March 31.

All STSM and grants must be completed by end of August 2025, to have the time to report and be reimbursed by end of September 2025

In the evaluation process YR have priority, even if senior scientists are welcome to apply.

Additional requirements will be included for approval that is the integration of drug research fields with environmental impacts outcome and declaration of

the Global development goals explicitly addressed. These requirements will apply starting from the 6th STSM calls.

Linkedin: <https://www.linkedin.com/groups/9557829/>

Youtube channel: <https://www.youtube.com/@OneHealthdrugs>

Website: <https://www.onehealthdrugs.com>

---

## Upcoming In-Person Events – Year 3

Join our exciting upcoming in-person and hybrid events scheduled for Year 3:

### **Conference in Antwerp, Belgium**

4–6 June 2025

**Workshop:** Surveillance, Prevention and Therapies Against Parasitic Diseases in Humans and Animals (Hybrid)

Tirana, Albania | 15–16 May 2025

[Details & Registration](#)

Contacts: Erjona Abazaj ([abazajerjona@gmail.com](mailto:abazajerjona@gmail.com)), Elton Rogozi ([eltonrogozi@yahoo.com](mailto:eltonrogozi@yahoo.com))

### **GP2A 2025 & Paul Ehrlich MedChem 2025 Co-organised with COST Action OneHealthdrugs**

Nantes, France | 11–13 June 2025

The Group for the Promotion of Pharmaceutical chemistry in Academia (GP2A) is a member-led network of academic medicinal chemists working in universities and research institutes in Europe.

Founded in 1992, as the Groupement des Pharmacochimistes de l’Arc Atlantique (GP2A) by medicinal chemists working within Schools of Pharmacy near the western coast of Europe (the “Atlantic Arc”), it has rapidly expanded and currently includes academic members from France, Spain, Germany, Portugal, Ireland, Italy

and the United Kingdom. Our definition of medicinal chemistry is broad and membership is open to those working in areas as diverse as physical and pharmaceutical chemistry and molecular pharmacology as well as the traditional areas of natural product chemistry, pharmacognosy and drug discovery. **This year the conference is co-organized with the COST Action OneHealthdrugs (CA21111)** and the Paul Ehrlich medchem network.

Our primary aim is networking to enable exchange of ideas and experience. This is facilitated through two major activities: Our annual scientific conference and PhD student and post-doctoral research exchanges.

The network provides bursaries to facilitate exchange between members' laboratories.

#### [Event Details & Registration](#)

COST Action Lecturer: Prof. Maria Laura Bolognesi

Reference: Prof. Pascal Marchand

#### **Erasmus Mundus Summer School in Chemoinformatics**

Ljubljana, Slovenia | 30 June–4 July 2025

Explore innovative AI-driven chemoinformatics methodologies. Co-organised by COST Action CA21111, featuring a dedicated session by Prof. Maria Paola Costi.

Explore Cutting-Edge Chemoinformatics and AI in Chemistry!

The Erasmus Mundus Summer School on Chemoinformatics is a prestigious international event supported by the Erasmus Mundus master's degree «Chemoinformatics+: Artificial Intelligence in Chemistry.» This well-established program gathers young and experienced scientists from academia and industry to explore AI-driven molecular and reaction design.

This event is **co-organized with the COST Action OneHealthdrugs (CA21111) as you can see in the inside program, with a session dedicated to OHD COST Action workshop.**

#### [Website & Registration](#)

Reference: Prof. Črtomir Podlipnik



## Training School in Riga, Latvia

8–10 September 2025

Organised by Emilio Parisini (Latvia) in collaboration with Marco Mazzorana (Oxford, UK), Andrea Ilari (Rome, Italy), and Cecilia Pozzi (Siena, Italy).

---

### Strategic Stakeholder Engagement – Driving Results Exploitation (Year 3)

In Year 3 of our COST Action, we're intensifying our strategic efforts on stakeholder engagement to achieve impactful results exploitation. Central to this strategy is the proactive integration of compound properties—such as sustainability, biodegradability, ecotoxicological effects, and regulatory considerations—right from the initial phases of drug discovery. Our stakeholder engagement initiative will:

**Facilitate targeted dialogue** among researchers, industry partners, policymakers, regulators, and public health authorities, ensuring alignment of research outputs with market needs and regulatory standards.

**Maximise knowledge exchange and collaboration**, helping bridge gaps between academia, industry, and regulatory bodies to streamline the path from innovative research to real-world applications.

**Accelerate the translation of research into actionable solutions**, ensuring that developed compounds meet high standards for efficacy, safety, and environmental impact from the outset.

**Establish feedback mechanisms** to capture stakeholder perspectives, enhancing the relevance and applicability of our research outcomes.

**Identify potential barriers** early in the drug development process, thereby reducing risks associated with market introduction, regulatory approval, and environmental compliance.

All members are encouraged to actively participate in these strategic discussions. Your involvement is essential in shaping a robust, practical, and environmentally responsible approach to drug discovery against vector-borne parasitic diseases.



To ensure these efforts are successful, we need your valuable input on identifying and analysing the right stakeholders.

---

## Give us your valuable feedback

---

We will be pleased to answer any questions you may have or consider suggestions for improving our Community.

Please email us at [onehealthdrugs.events@gmail.com](mailto:onehealthdrugs.events@gmail.com)

Contact us if you have any questions,  
suggestions or you wish to share your news



